Search - tctmd.com

Displaying 61 - 80 of 20424

Sort: Relevancy | Date

News Daily News

Many PE Teams Embraced Mechanical Thrombectomy Early On: PERT Registry

L.A. McKeown

March 06, 2026

News Daily News

Advanced HF in Finland: Costs, Survival Diverge for Elective vs Urgent LVAD

Caitlin E. Cox

March 06, 2026

News Conference News THT 2026

Baroreflex Activation for Advanced HF Yields Positive Results: Postmarketing Data

Todd Neale

March 05, 2026

News Daily News

HBR Common, Impactful Among All-Comer Acute MI Patients

Yael L. Maxwell

March 05, 2026

News Conference News THT 2026

Optimal BP After HeartMate 3 LVAD May Be Higher Than Previously Thought

Todd Neale

March 04, 2026

News Conference News CRT 2026

CRT 2026: What to Expect in Washington, DC

L.A. McKeown

March 04, 2026

News Conference News THT 2026

NT-proBNP Provides Info on Who Will Fare Well After Tricuspid TEER

Todd Neale

March 04, 2026

Presentation THT 2026

Healthcare Systems Harnessing Their Own Data for Evidence, Generation, Dissemination, and Influencing Clinical Practice — Example 2

Presenter: Nir Uriel

March 04, 2026

Presentation THT 2026

How Will Guideline Committees View Results From RWE Trials?

Presenter: Paul Heidenrich

March 04, 2026

Presentation THT 2026

AHA and C3TN Shock Networks

Presenter: Shashank Shekhar Sinha

March 04, 2026

Presentation THT 2026

Cardiogenic Shock Working Group: Triumphs and Tribulations

Presenter: Rachna Kataria

March 04, 2026

Presentation THT 2026

Hemodynamic Frontiers in Heart Failure (HF2) Registry: Goals and Achievements

Presenter: Tom Heywood

March 04, 2026

Presentation THT 2026

Virtual Randomized Clinical Trials: Learnings From DANLOGIC-HF

Presenter: Tor Biering-Sørensen

March 04, 2026

Presentation THT 2026

Statistical Approaches for Developing Credible Evidence of Safety and Effectiveness for HF Devices From Real World Data: An Overview for the Clinician

Presenter: Issa Dahabreh

March 04, 2026

Presentation THT 2026

Real World Databases: What Is Required for Their Use To Substitute for Randomized Trials for Device Approvals, Reimbursement and Label Expansion

Presenter: Robert W. Yeh

March 04, 2026

Presentation THT 2026

Time for a Separate Guideline Path for HF Devices?

Presenter: Javed Butler

March 04, 2026

Presentation THT 2026

Clinical Feasibility Study of the Magenta Elevate™ percutaneous Left Ventricular Assist Device (pLVAD) System in Patients with Cardiogenic Shock (ELEVATE™ CS FIH)

Presenter: David Israeli

March 04, 2026

Presentation THT 2026

Revisiting Surrogate Endpoints in Clinical Trials of HF Devices

Presenter: James Januzzi

March 04, 2026

Presentation THT 2026

The Elephant in the Room: How To Deal With PROs in Non-Sham Controlled Studies

Presenter: Gregg W. Stone

March 04, 2026

Presentation THT 2026

Revisiting Patient Reported Outcomes — Can they Be Improved for Device Trials and Account for Mortality?

Presenter: John A. Spertus

March 04, 2026

Advertisement

Many PE Teams Embraced Mechanical Thrombectomy Early On: PERT Registry

Advanced HF in Finland: Costs, Survival Diverge for Elective vs Urgent LVAD

Baroreflex Activation for Advanced HF Yields Positive Results: Postmarketing Data

HBR Common, Impactful Among All-Comer Acute MI Patients

Optimal BP After HeartMate 3 LVAD May Be Higher Than Previously Thought

CRT 2026: What to Expect in Washington, DC

NT-proBNP Provides Info on Who Will Fare Well After Tricuspid TEER

Healthcare Systems Harnessing Their Own Data for Evidence, Generation, Dissemination, and Influencing Clinical Practice — Example 2

How Will Guideline Committees View Results From RWE Trials?

AHA and C3TN Shock Networks

Cardiogenic Shock Working Group: Triumphs and Tribulations

Hemodynamic Frontiers in Heart Failure (HF2) Registry: Goals and Achievements

Virtual Randomized Clinical Trials: Learnings From DANLOGIC-HF

Statistical Approaches for Developing Credible Evidence of Safety and Effectiveness for HF Devices From Real World Data: An Overview for the Clinician

Real World Databases: What Is Required for Their Use To Substitute for Randomized Trials for Device Approvals, Reimbursement and Label Expansion

Time for a Separate Guideline Path for HF Devices?

Clinical Feasibility Study of the Magenta Elevate™ percutaneous Left Ventricular Assist Device (pLVAD) System in Patients with Cardiogenic Shock (ELEVATE™ CS FIH)

Revisiting Surrogate Endpoints in Clinical Trials of HF Devices

The Elephant in the Room: How To Deal With PROs in Non-Sham Controlled Studies

Revisiting Patient Reported Outcomes — Can they Be Improved for Device Trials and Account for Mortality?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content